Capital Investment Counsel LLC Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Investment Counsel LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,842 shares of the biopharmaceutical company’s stock after selling 229 shares during the quarter. Capital Investment Counsel LLC’s holdings in Gilead Sciences were worth $5,158,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Algert Global LLC purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $254,000. Creative Planning boosted its holdings in Gilead Sciences by 8.4% in the second quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company’s stock valued at $12,939,000 after acquiring an additional 14,544 shares in the last quarter. Magnolia Capital Advisors LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at $461,000. Sunbelt Securities Inc. raised its holdings in Gilead Sciences by 35.1% in the 2nd quarter. Sunbelt Securities Inc. now owns 15,678 shares of the biopharmaceutical company’s stock worth $1,076,000 after purchasing an additional 4,075 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Citigroup assumed coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Robert W. Baird lifted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. BMO Capital Markets increased their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Mizuho boosted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $93.85 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average price of $91.88 and a 200-day moving average price of $85.27. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market capitalization of $116.96 billion, a PE ratio of 1,042.78, a P/E/G ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.